secwatch.observer — SEC 8-K summary
======================================

Issuer:     LENZ Therapeutics, Inc. (LENZ)
CIK:        0001815776
Form:       8-K
Filed at:   2025-07-31T23:59:59+00:00
Accession:  0001815776-25-000059
Event type: regulatory
Sentiment:  positive
Materiality: 0.90
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LENZ Therapeutics receives FDA approval for VIZZ (aceclidine) to treat presbyopia
--------------------------------------------------------------------------------

- VIZZ (aceclidine ophthalmic solution) 1.44% approved by FDA for presbyopia, impacting ~128M US adults.
- First and only aceclidine-based eye drop; once-daily dosing with proven efficacy up to 10 hours.
- Samples and commercial availability expected as early as October 2025; sales activities to begin immediately.
- Approval based on three Phase 3 studies (CLARITY 1,2,3) showing rapid onset within 30 min and consistent near-vision improvement.
- Well-tolerated; most common adverse reactions were instillation site irritation, dim vision, headache, mostly mild and self-resolving.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815776/000181577625000059/0001815776-25-000059-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815776/000181577625000059/lenz-20250731.htm
  HTML page:      https://secwatch.observer/filing/0001815776-25-000059

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer